Business Context and Reporting Period
Company: Bio Green Med Solution, Inc. (Delaware corporation, Nasdaq Capital Market)
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2026
Event: Entry into a Material Definitive Agreement (Business Combination Agreement) with Future NRG Sdn. Bhd. ("FNRG"), a Malaysian private limited company.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for the reporting period.
Transaction Structure:
- Exchange Ratio: FNRG shareholders will exchange ordinary shares for Bio Green Med Solution common stock.
- Pro Forma Ownership: Selling Shareholders of FNRG will own approximately more than 99% of the combined company; pre-Exchange Bio Green Med Solution stockholders will own approximately less than 1%.
- Tax Status: The transaction is intended to qualify as a tax-free reorganization under Section 351 of the Internal Revenue Code.
Material Changes and Transaction Terms
The primary material change is the proposed reverse merger where FNRG becomes a wholly-owned subsidiary of Bio Green Med Solution, Inc.
- Board Composition: Post-transaction, the Board is expected to have five members: four designated by the Company (including current members except Mr. Kiu Cu Seng) and one designated by FNRG (Mr. Pun Kah Weng).
- Lock-Up Agreements: Certain Selling Shareholders agreed not to transfer acquired shares for 180 days following the closing.
- Termination Rights: Either party may terminate the agreement if the Exchange is not closed by December 31, 2026.
- Stock Split: The Company may seek shareholder approval for a reverse stock split of its common stock if deemed necessary.
Guidance, Outlook, and Risks
Conditions Precedent: Closing is subject to:
- Approval by Company stockholders of the Business Combination Agreement and related proposals.
- Approval by FNRG Selling Shareholders.
- Nasdaq approval for listing the new shares.
- Effectiveness of the SEC Registration Statement (Form S-4).
- Written agreement on the final number of Exchange Shares.
Risks and Contingencies:
- Failure to obtain required regulatory or shareholder approvals.
- Inability to meet Nasdaq listing standards.
- Uncertainty regarding projected financial information for FNRG.
- General market, political, and legal conditions affecting the transaction.
Management Commentary: The Company issued a press release on June 4, 2026, announcing the execution of the agreement. No specific financial guidance or revenue outlook was provided in this filing.
Investor Verification Checklist
- Verify the final exchange ratio and the exact number of shares to be issued upon closing.
- Review the upcoming Form S-4 (Proxy Statement/Prospectus) for detailed financial data on FNRG and the combined entity.
- Confirm the outcome of the shareholder vote required to approve the transaction.
- Monitor Nasdaq's decision regarding the listing of the new shares.
- Check for any amendments to the Business Combination Agreement prior to the December 31, 2026 termination deadline.